Nasus Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	1.24	0.28	0.19	0.15
Short-Term Investments	3.05	-	-	-
Cash & Short-Term Investments	4.29	0.28	0.19	0.15
Cash Growth	1409.15%	47.15%	25.32%	-
Other Current Assets	0.57	0.17	0.25	0.26
Total Current Assets	4.86	0.46	0.44	0.42
Net Property, Plant & Equipment	0.15	-	-	-
Other Long-Term Assets	-	0.26	-	-
Total Assets	5	0.72	0.44	0.42
Accounts Payable	0.83	0.65	0.66	0.77
Accrued Expenses	0.81	0.99	0.62	0.35
Short-Term Debt	-	1.8	2.46	1.57
Current Portion of Leases	0.05	-	-	-
Other Current Liabilities	0.48	0.49	0.51	0.51
Total Current Liabilities	2.16	3.93	4.24	3.2
Long-Term Leases	0.07	-	-	-
Total Long-Term Liabilities	0.07	-	-	-
Total Liabilities	2.24	3.93	4.24	3.2
Common Stock	-	0.02	0.02	0
Additional Paid-in Capital	21.29	9.43	7.32	7.29
Retained Earnings	-18.52	-12.66	-11.13	-10.08
Shareholders' Equity	2.77	-3.21	-3.8	-2.79
Total Liabilities & Equity	5	0.72	0.44	0.42
Total Debt	0.12	1.8	2.46	1.57
Net Cash (Debt)	4.17	-1.52	-2.26	-1.42
Net Cash Per Share	0.52	-0.22	-0.32	-0.21
Book Value	2.77	-3.21	-3.8	-2.79
Book Value Per Share	0.35	-0.46	-0.54	-0.40
Tangible Book Value	2.77	-3.21	-3.8	-2.79
Tangible Book Value Per Share	0.35	-0.46	-0.54	-0.40

Updated Mar 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q